Comprehensive astigmatism planning and analysis with AMARIS

Session Details

Session Title: Photoablation

Session Date/Time: Tuesday 13/09/2016 | 14:00-16:00

Paper Time: 15:09

Venue: Hall C2

First Author: : M.Arbelaez OMAN

Co Author(s): :    N. Alpins   G. Stamatelatos   S. Verma   J. Arbelaez   S. Arba Mosquera        

Abstract Details

Purpose:

To evaluate the clinical outcomes of different optimized astigmatism plan strategies based upon manifest refraction and corneal cylinder. Aberration-Free CAM treatments have been performed in all cases.

Setting:

Muscat Eye Laser Center ( muscat - Oman)

Methods:

The planning of optimized astigmatic corrections based upon corneal and manifest astigmatism has been evaluated at 3M follow-up in 200 eyes showing ORA >0,75D pre-operative. 100 treatments based upon manifest astigmatism, and 100 treatments on optimized astigmatic corrections based upon corneal and manifest astigmatism (vector planning group). In all cases standard examinations, pre- and postoperative corneal-wavefront analyses (OPTIKON Scout), and ocular-wavefront aberrometries (Ocular Wavefront Analyzer) were performed. CAM software was used to plan Aberration-Free treatments and AMARIS system was used to perform ablations (SCHWIND eye-tech-solutions). Optimized astigmatic corrections were evaluated in terms of efficacy, predictability, stability, safety, and aberrations outcomes.

Results:

Vector Planning shows no inferiority vs. manifest Rx planning. UDVA and CDVA outcomes are similar (p>0.05) and excellent in both groups (mean VA -0.05±0.10logMAR). Postoperative Refractions are similar (p>0.05) and excellent in both groups (mean SE -0.05±0.20D; mean Ast -0.3±0.2D). Corneal toricity was smaller (p<0.05) in vector planning group (mean toricity 0.6±0.4D in vector planning group; 0.9±0.4D in manifest refraction group).

Conclusions:

The slight superiority in the vector planning group could be attributed to: 1. Uncertainty in manifest Rx vs. objective measurement of corneal toricity 2. Corneal toricity as main driver of manifest astigmatism 3. Going half-way (60%-40%) represents a sort of optimum balance for minimum residual risk

Financial Disclosure:

... gains financially from product or procedure presented, ... travel has been funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company